{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:39:29Z","timestamp":1790710769022,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.canlet.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T03:56:59Z","timestamp":1628740619000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Albendazole inhibits NF-\u03baB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma"],"prefix":"10.1016","volume":"520","author":[{"given":"Hui","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiqun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongwen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanjie","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.08.009_bib1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.08.009_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.08.009_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.canlet.2021.08.009_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1756-8722-6-91","article-title":"Fact or fiction--identifying the elusive multiple myeloma stem cell","volume":"6","author":"Kellner","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2021.08.009_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clml.2017.09.020","article-title":"Two states of myeloma stem cells","volume":"18","author":"Yaccoby","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.canlet.2021.08.009_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.03.048","article-title":"Side population cells in human cancers","volume":"268","author":"Wu","year":"2008","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2021.08.009_bib7","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","article-title":"Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications","volume":"117","author":"Jakubikova","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.08.009_bib8","first-page":"651","article-title":"New drugs are not enough-drug repositioning in oncology: an update","volume":"56","author":"Armando","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2021.08.009_bib9","doi-asserted-by":"crossref","first-page":"e2247","DOI":"10.1371\/journal.pntd.0002247","article-title":"Association between response to albendazole treatment and \u03b2-tubulin genotype frequencies in soil-transmitted helminths","volume":"7","author":"Diawara","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.canlet.2021.08.009_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3835(01)00382-2","article-title":"In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole","volume":"165","author":"Pourgholami","year":"2001","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2021.08.009_bib11","first-page":"425","article-title":"Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis, Cancer Chemother","volume":"55","author":"Pourgholami","year":"2005","journal-title":"Pharma"},{"key":"10.1016\/j.canlet.2021.08.009_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2407-10-143","article-title":"Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole","volume":"10","author":"Pourgholami","year":"2010","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2021.08.009_bib13","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","article-title":"Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice","volume":"12","author":"Pourgholami","year":"2006","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.08.009_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bcp.2018.11.003","article-title":"Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3\/ROS\/p38 MAPK\/TTP axis-mediated TNF-\u03b1 upregulation","volume":"162","author":"Wang","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.08.009_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.redox.2016.09.013","article-title":"Albendazole as a promising molecule for tumor control","volume":"10","author":"Castro","year":"2016","journal-title":"Redox Biol"},{"key":"10.1016\/j.canlet.2021.08.009_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050655","article-title":"A role for NF-\u03baB in organ specific cancer and cancer stem cells","volume":"11","author":"Kaltschmidt","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.08.009_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s13402-015-0236-6","article-title":"NF-\u03baB signaling in cancer stem cells: a promising therapeutic target?","volume":"38","author":"Vazquez-Santillan","year":"2015","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2021.08.009_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ncomms1159","article-title":"Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-\u03baB signalling","volume":"2","author":"Rajasekhar","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.08.009_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s13058-014-0444-4","article-title":"Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF\u03baB) pathway","volume":"16","author":"Colavito","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2021.08.009_bib20","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1172\/JCI45797","article-title":"Crosstalk between the canonical NF-\u03baB and Notch signaling pathways inhibits Ppar\u03b3 expression and promotes pancreatic cancer progression in mice","volume":"121","author":"Maniati","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.08.009_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vrabel","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.canlet.2021.08.009_bib22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2021.08.009_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.08.009_bib24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.08.009_bib25","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","article-title":"Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells","volume":"6","author":"Markovina","year":"2008","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.canlet.2021.08.009_bib26","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1074\/jbc.RA117.000667","article-title":"Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-\u03baB activity and increases drug resistance in multiple myeloma","volume":"293","author":"Huynh","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.08.009_bib27","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.08.009_bib28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2021.08.009_bib29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2013.383","article-title":"ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2021.08.009_bib30","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1080\/15384101.2014.998067","article-title":"Ibrutinib inhibits BTK-driven NF-\u03baB p65 activity to overcome bortezomib-resistance in multiple myeloma","volume":"14","author":"Murray","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2021.08.009_bib31","doi-asserted-by":"crossref","first-page":"104993","DOI":"10.1016\/j.antiviral.2020.104993","article-title":"The NF-\u03baB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses","volume":"185","author":"Mendoza","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.canlet.2021.08.009_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.drudis.2015.09.003","article-title":"Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives","volume":"21","author":"Bulusu","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2021.08.009_bib33","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.4110\/in.2020.20.e29","article-title":"The antitumor potentials of benzimidazole anthelmintics as repurposing drugs","volume":"20","author":"Son","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.canlet.2021.08.009_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6020059","article-title":"The NF-\u03baB activating pathways in multiple myeloma","volume":"6","author":"Roy","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2021.08.009_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.08.009_bib36","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-12-0779","article-title":"Dual inhibition of canonical and noncanonical NF-\u03baB pathways demonstrates significant antitumor activities in multiple myeloma","volume":"18","author":"Fabre","year":"2012","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.08.009_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056399","article-title":"The role of NF-\u03baB signaling in the maintenance of pluripotency of human induced pluripotent stem cells","volume":"8","author":"Takase","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.08.009_bib38","doi-asserted-by":"crossref","first-page":"37340","DOI":"10.1038\/srep37340","article-title":"NF-kappa\u0392-inducing kinase regulates stem cell phenotype in breast cancer","volume":"6","author":"Vazquez-Santillan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2021.08.009_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.matbio.2019.11.004","article-title":"Heparanase promotes myeloma stemness and in vivo tumorigenesis","volume":"88","author":"Tripathi","year":"2020","journal-title":"Matrix Biol."},{"key":"10.1016\/j.canlet.2021.08.009_bib40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","article-title":"RAR\u03b12 expression confers myeloma stem cell features","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.08.009_bib41","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/bjh.16477","article-title":"Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt\/\u03b2-catenin pathway","volume":"189","author":"Wang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2021.08.009_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12951-015-0082-8","article-title":"Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model","volume":"13","author":"Noorani","year":"2015","journal-title":"J. Nanobiotechnol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521003980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521003980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:02:06Z","timestamp":1759593726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521003980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"alternative-id":["S0304383521003980"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.08.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albendazole inhibits NF-\u03baB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}